Skip to main content
. Author manuscript; available in PMC: 2020 May 1.
Published in final edited form as: J Allergy Clin Immunol. 2018 Nov 12;143(5):1865–1877.e4. doi: 10.1016/j.jaci.2018.08.053

FIG 4. CRF2 selective antagonism enhances mast cell degranulation in rodent and human mast cells.

FIG 4.

β-hex % release from RBL-2H3 mast cells (A) and human LAD2 cells (B) following pre-treatment with the CRF2 antagonist drug Astressin 2B (A2B) at indicated concentrations. **p<0.01 1-Way ANOVA (n=6 replicates/treatment). Experiments repeated in n=3 independent experiments.